foscarnet has been researched along with efavirenz in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (66.67) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dornadula, G; Grobler, JA; Hazuda, DJ; Miller, MD; Rice, MR; Simcoe, AL | 1 |
| Chou, KC; González-Díaz, H; Martinez de la Vega, O; Prado-Prado, FJ; Ubeira, FM; Uriarte, E | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
1 review(s) available for foscarnet and efavirenz
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
2 other study(ies) available for foscarnet and efavirenz
| Article | Year |
|---|---|
HIV-1 reverse transcriptase plus-strand initiation exhibits preferential sensitivity to non-nucleoside reverse transcriptase inhibitors in vitro.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Benzoxazoles; Cyclopropanes; DNA; Dose-Response Relationship, Drug; Drug Resistance, Viral; Enzyme Inhibitors; HIV Reverse Transcriptase; In Vitro Techniques; Inhibitory Concentration 50; Ligands; Models, Genetic; Oxazines; Pyridones; Reverse Transcriptase Inhibitors; Stochastic Processes; Transcription, Genetic; Virus Replication | 2007 |
Unified QSAR approach to antimicrobials. 4. Multi-target QSAR modeling and comparative multi-distance study of the giant components of antiviral drug-drug complex networks.
Topics: Anti-Infective Agents; Antiviral Agents; Artificial Intelligence; Computer Simulation; Drug Evaluation, Preclinical; Molecular Structure; Quantitative Structure-Activity Relationship | 2009 |